J. Sederias

发表

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

L. Seymour, J. Lyons, S. Gibson, 2017, Leukemia & lymphoma.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

H. Feilotter, L. Seymour, F. Shepherd, 2018, Lung cancer.

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

L. Seymour, T. Reiman, D. Reece, 2016, Leukemia & lymphoma.

Inhibition of Chara vulgaris oospore germination by sulfidic sediments.

B. Colman, J. Sederias, 2009 .

A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b

E. Eisenhauer, A. Oza, D. Provencher, 2008 .

The interaction of light and low temperature on breaking the dormancy of Chara vulgaris oospores

B. Colman, J. Sederias, 2007 .

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

H. Mackay, E. Eisenhauer, A. Oza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

E. Eisenhauer, A. Oza, H. Hirte, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

A. Oza, E. Eisenhauer, S. Ellard, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

S. Weiss, W. Mason, L. Seymour, 2019, Investigational New Drugs.

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.

A. Tinker, H. Mackay, E. Eisenhauer, 2010, Gynecologic oncology.

Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179.

E. Eisenhauer, A. Oza, H. Hirte, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

L. Seymour, M. Mencoboni, F. Grosso, 2023, Journal of Clinical Oncology.

Propagation of chara vulgaris using sediment seed bank oospores and vegetative biomass / for Wisutec

J. Sederias, 2003 .

Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).

C. Gridelli, L. Cavanna, L. Seymour, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

E. Eisenhauer, A. Oza, S. Ellard, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185

E. Eisenhauer, A. Oza, S. Ellard, 2008 .

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

C. Gridelli, G. Ceresoli, M. Piccirillo, 2023, The Lancet.